Yazar "Yılmaz, Yusuf" için listeleme
-
Addressing the looming epidemic of metabolic dysfunction-associated steatotic liver disease in Pakistan: A call for action
Kamani, Lubna; Rahat, Adeel; Yılmaz, Yusuf (Kare Publishing, 2024)The term metabolic dysfunction-associated steatotic liver disease (MASLD), which evolved from its predecessor, nonalcoholic fatty liver disease (NAFLD),[1] -
Alternative splicing: hallmark and therapeutic opportunity in metabolic liver disease
Jiang, Mingqian; Alqahtani, Saleh A.; Seto, Wai-Kay; Yılmaz, Yusuf; Pan, Ziyan; Valenti, Luca; Eslam, Mohammed (Oxford University Press, 2025)Metabolic dysfunction-associated fatty liver disease (MAFLD) has become the leading cause of chronic liver disease worldwide, with fibrosis recognized as the main prognostic factor and therapeutic target. While early-stage ... -
Aramchol improves hepatic fibrosis in MASH: Results of multimodality assessment using both conventional and digital pathology
Ratziu, Vlad; Yılmaz, Yusuf; Lazas, Don; Friedman, Scott L.; Lackner, Caroline; Behling, Cynthia; Cummings, Oscar W.; Chen, Li; Petitjean, Matthieu; Gilgun-Sherki, Yossi; Gorfine, Tali; Kadosh, Shaul; Eyal, Eli; Sanyal, Arun J. (Wolters Kluwer Medknow Publications, 2024)Background and aims: Antifibrotic trials rely on conventional pathology (CP) despite recognized limitations. We compared single fiber digital image analysis (DIA) with CP to quantify the antifibrotic effect of Aramchol, a ... -
Asia-Pacific association for study of liver guidelines on management of ascites in liver disease
Singh, Virendra; De, Arka; Mehtani, Rohit; Angeli, Paolo; Maiwall, Rakhi; Satapathy, Sanjaya; Singal, Ashwini K.; Saraya, Anoop; Sharma, B. C.; Eapen, C. E.; Rao, P. N.; Shukla, Akash; Shalimar; Choudhary, Narendra S.; Alcantara-Payawal, Diana; Arora, Vinod; Aithal, Guru; Kulkarni, Anand; Roy, Akash; Shrestha, Ananta; al Mahtab, Mamun; Niriella, Madunil A.; Siam, Tan Soek; Zhang, Chun-Qing; Huei, Lee Guan; Yu, Ming-Lung; Roberts, Stuart K.; Peng, Cheng-Yuan; Chen, Tao; George, Jacob; Wong, Vincent; Yılmaz, Yusuf; Treeprasertsuk, Sombat; Kurniawan, Juferdy; Kim, Seung Up; Younossi, Zobair M.; Sarin, Shiv Kumar (Springer, 2023)The development of ascites is a landmark event in the natural history of cirrhosis. -
The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease
Eslam, Mohammed; Fan, Jian-Gao; Yu, Ming-Lung; Wong, Vincent Wai-Sun; Cua, Ian Homer; Liu, Chun-Jen; Tanwandee, Tawesak; Gani, Rino; Seto, Wai-Kay; Alam, Shahinul; Young, Dan Yock; Hamid, Saeed; Zheng, Ming-Hua; Kawaguchi, Takumi; Chan, Wah-Kheong; Payawal, Diana; Tan, Soek-Siam; Goh, George Boon-bee; Strasser, Simone I.; Viet, Hang Dao; Kao, Jia-Horng; Kim, Won; Kim, Seung Up; Keating, Shelley E.; Yılmaz, Yusuf; Kamani, Lubna; Wang, Chia-Chi; Fouad, Yasser; Abbas, Zaigham; Treeprasertsuk, Sombat; Thanapirom, Kessarin; Al Mahtab, Mamun; Lkhagvaa, Undram; Baatarkhuu, Oidov; Choudhury, Ashok Kumar; Stedman, Catherine A. M.; Chowdhury, Abhijit; Dökmeci, A Kadir; Wang, Fu-Sheng; Lin, Han-Chieh; Huang, Jee-Fu; Howell, Jess; Jia, Jidong; Alboraie, Mohamed; Roberts, Stuart K.; Yoneda, Masato; Ghazinian, Hasmik; Mirijanyan, Aram; Nan, Yuemin; Lesmana, Cosmas Rinaldi Adithya; Adams, Leon A.; Shiha, Gamal; Kumar, Manoj; Örmeci, Necati; Wei, Lai; Lau, George; Omata, Masao; Sarin, Shiv K.; George, Jacob (Springer, 2025)Metabolic dysfunction-associated fatty liver disease (MAFLD) affects over one-fourth of the global adult population and is the leading cause of liver disease worldwide. To address this, the Asian Pacific Association for ... -
Association of diet quality scores with risk of metabolic-associated fatty liver disease in Iranian population: a nested case-control study
Taheri, Ehsaneh; Yılmaz, Yusuf; Ghorat, Fereshteh; Moslem, Alireza; Zali, Mohammad Reza (Springer Science and Business Media Deutschland GmbH, 2024)Background and aim: A healthy diet has been recommended for non-alcoholic fatty liver disease (NAFLD). We aim to investigate the associations of diet quality indices with the risk of developingmetabolic-associated fatty ... -
Association of metabolic dysfunction-associated fatty liver disease with cognitive impairment and all-cause dementia: A comprehensive review
Kaya, Eda; Yılmaz, Yusuf (AVES, 2024)Metabolic dysfunction-associated fatty liver disease (MAFLD) is a significant public health concern, affecting one-third of the global population and posing a risk for progressive liver disease. MAFLD is characterized by ... -
Body mass index and diabetes predict severity of liver fibrosis across the spectrum of steatotic liver disease
Kaya, Eda; Vilar-Gomez, Eduardo; Vuppalanchi, Raj; Yılmaz, Yusuf (Elsevier, 2025)Introduction and Objectives: Recent evidence indicates that metabolic dysfunction and alcohol-associated steatotic liver disease (MetALD), a newly defined subgroup of steatotic liver disease (SLD), may have a worse prognosis ... -
Brushing your teeth may be good for your liver: Linking oral health to non-alcoholic fatty liver disease
Yılmaz, Yusuf (Elsevier, 2023)he study by Pischke et al. [1], which explores the relationships between non-alcoholic steatohepatitis (NASH) and periodontitis, warrants commendation. The analysis involved 32 patients with NASH and 100 randomly, ... -
Can frequent toothbrushing reduce the risk of cirrhosis among patients with non-alcoholic fatty liver disease? Hints from a registry-based study
Keklikkıran, Çağlayan; Stepanova, Maria; Younossi, Zobair; Yılmaz, Yusuf (Karger, 2023)Introduction: While poor oral hygiene has been previously associated with an increased risk of non-alcoholic fatty liver disease (NAFLD), its association with hepatic fibrosis remains unclear. Here, we sought to analyze ... -
Changes in the etiology of chronic liver disease by referral to a FibroScan center: Increasing prevalence of the nonalcoholic fatty liver disease
Eriş, Tansu; Hassan, Moomen; Hikal, Yousra; Sawah, Enas; Daneshgar, Fatemeh; Teker, Ayşe Gülşen; Özel, Furkan; Lüleci, Nimet Emel; Kaya, Eda; Yılmaz, Yusuf (Kare Publishing, 2023)Background and Aim: Chronic liver disease (CLD) is a leading cause of morbidity and mortality worldwide with a wide etiological spectrum. Fi-broScan (R) is used for follow-up of fibrosis and steatosis. This single -cen-ter ... -
Chronic hepatitis B and metabolic dysfunction-associated steatotic liver disease: Metabolic risk factors are key drivers of hepatocellular carcinoma
Adalı, Gupse; Aykut, Hüseyin; Bilgiç, Nermin Mutlu; Yılmaz, Yusuf (Elsevier, 2024)Objective: Chronic hepatitis B (CHB) and metabolic dysfunction-associated steatotic liver disease (MASLD) are the leading causes of hepatocellular carcinoma (HCC). This study aimed to explore the impact of baseline MASLD ... -
Chronotype preference, sleep quality, and night-eating behaviors in patients with metabolic dysfunction-associated steatotic liver disease: Assessing the relationship with disease severity and fibrosis
Sakallı Kanı, Ayşe; Özercan, Ahmet; Kanı, Haluk Tarık; Eren, Fatih; Sayar, Kemal; Yılmaz, Yusuf (Kare Publishing, 2023)Background and Aim: Our primary objective is to examine the variance in chronotype, night-eating patterns, and sleep quality in patients with biopsy-proven metabolic dysfunction-associated steatotic liver disease. In ... -
Clinical and biochemical characteristics of a danish and turkish cohort of incident and prevalent patients with primary biliary cholangitis
Eruzun, Hasan; Bossen, Lars; Gökçe, Dilara Turan; Ergenç, İlkay; Harput, Zekiye Nur; Aydemir, Neslihan Güneş; Kayhan, Meral Akdoğan; Yapıcı, Hasan Basri; Doğan, Tugay; Holland-Fischer, Peter; Hansen, Jesper Bach; Yılmaz, Yusuf; Sezgin, Orhan; Adanır, Haydar; Bektaş, Ahmet; Grønbæk, Henning (AVES, 2025)Background/Aims: Primary biliary cholangitis (PBC) is a chronic liver disease influenced by environmental, genetic, and epigenetic factors, with varying incidence across populations. This study compared demographic, ... -
Clinical and patient-reported outcome profile of patients with hepatitis B viral infection from the Global Liver Registry (TM)
Younossi, Zobair M.; Yu, Ming-Lung; Yılmaz, Yusuf; Alswat, Khalid Aida; Buti, Maria; Fernandez, Marlen Ivon Castellanos; Papatheodoridis, Georgios; Hamid, Saeed S.; El-Kassas, Mohamed; Chan, Wah Kheong; Duseja, Ajay K.; Gordon, Stuart C.; Eguchi, Yuichiro; Isakov, Vasily A.; Roberts, Stuart K.; Fan, Jian-Gao; Singal, Ashwani K.; Romero-Gomez, Manuel; Ahmed, Aijaz; Ong, Janus; Lam, Brian P.; Younossi, Issah; Nader, Fatema; Racila, Andrei; Stepanova, Maria; Alqahtani, Saleh (Wiley, 2023)Chronic hepatitis B (CHB) infection is one of the most common causes of cirrhosis and liver cancer worldwide. Our aim was to assess clinical and patient-reported outcome (PRO) profile of CHB patients from different regions ... -
Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt
Alqahtani, Saleh A.; Yılmaz, Yusuf; El-Kassas, Mohamed; Alswat, Khalid; Sanai, Faisal; AlZahrani, May; Abaalkhail, Faisal; AlShaikh, Manal; Stepanova, Maria; Younossi, Zobair M. (Wiley, 2024)Patients with chronic liver disease (CLD) experience health-related quality of life (HRQoL) and patient-reported outcomes (PROs) impairments. We assessed and identified predictors of HRQoL and PROs in CLD patients from ... -
Clinical insights on resmetirom: clinical indications, patient selection, and monitoring response to therapy
Kaya, Eda; Yılmaz, Yusuf; Alkhouri, Naim (Lippincott Williams and Wilkins, 2025)The recent conditional approval by the Food and Drug Administration of resmetirom for treating metabolic dysfunction-associated steatohepatitis (MASH) with significant or advanced fibrosis represents a pivotal milestone ... -
Deciphering the implications of MAFLD and MASLD definitions in the NAFLD population: Results from a single-center biopsy study
Kaya, Eda; Yılmaz, Yusuf (Wolters Kluwer Medknow Publications, 2024)To the Editor: The nomenclature for steatotic liver disease has been a topic of debate since 2020. The conventional expression, non-alcoholic fatty liver disease (NAFLD), was introduced in 1980 to describe the occurrence ... -
Decoding 17-beta-hydroxysteroid dehydrogenase 13: a multifaceted perspective on its role in hepatic steatosis and associated disorders
Demirtaş, Coşkun Özer; Yılmaz, Yusuf (Xia & He P)Chronic liver disease (CLD) represents a significant global health burden, with hepatic steatosis-associated disorders-such as metabolic dysfunction-associated steatohepatitis (MASH), alcoholic liver disease, and hepatitis ... -
Diagnostic accuracy of non-invasive tests to screen for at-risk MASH-An individual participant data meta-analysis
Mozes, Ferenc E.; Lee, Jenny A.; Vali, Yasaman; Selvaraj, Emmanuel A.; Jayaswal, Arjun N. A.; Boursier, Jerome; de Ledinghen, Victor; Lupsor-Platon, Monica; Yılmaz, Yusuf; Chan, Wah-Kheong; Mahadeva, Sanjiv; Karlas, Thomas; Wiegand, Johannes; Tsochatzis, Emmanouil; Liguori, Antonio; Wong, Vincent Wai-Sun; Lee, Dae Ho; Holleboom, Adriaan G.; van Dijk, Anne-Marieke; Mak, Anne Linde; Hagstroem, Hannes; Akbari, Camilla; Hirooka, Masash; Lee, Dong Hyeon; Kim, Won; Okanoue, Takeshi; Shima, Toshihide; Nakajima, Atsushi; Yoneda, Masato; Thuluvath, Paul J.; Li, Feng; Berzigotti, Annalisa; Mendoza, Yuly P.; Noureddin, Mazen; Truong, Emily; Fournier-Poizat, Celine; Geier, Andreas; Tuthill, Theresa; Yunis, Carla; Anstee, Quentin M.; Harrison, Stephen A.; Bossuyt, Patrick M.; Pavlides, Michael (Wiley, 2024)Background & Aims: There is a need to reduce the screen failure rate (SFR) in metabolic dysfunction-associated steatohepatitis (MASH) clinical trials (MASH+F2-3; MASH+F4) and identify people with high-risk MASH (MASH+F2-4) ...
